article · 2013
Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
Roberta Schmieder, Florian Puehler, Roland Neuhaus, Maria Kissel, Alex A. Adjei, Jeffrey N. Miner, Dominik Mumberg, Karl Ziegelbauer
55 citationsNeoplasiaDOI: https://doi.org/10.1593/neo.13812Open access